- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SIENTRA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 302,80 | -0,13 % | UnitedHealth Group Aktie steigt nach starken Quartalszahlen | ||
| THERMO FISHER | 399,90 | -0,22 % | Qualitätsaktie: Thermo Fisher: Aktie des Laborausrüsters vor bewegenden Zeiten! | © Foto: Sebastian Gollnow/dpaThermo Fisher: Die Aktie des US-amerikanischen Unternehmens kommt einfach nicht vom Fleck. Können da die Earnings helfen?Die Aktie von Thermo Fisher tut sich momentan schwer.... ► Artikel lesen | |
| TELADOC HEALTH | 4,914 | +0,22 % | Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know | ||
| ROKU | 97,74 | -0,59 % | The Only Reason to Consider Owning Roku for Less Than 3 Years | ||
| RESMED | 187,25 | -0,16 % | Resmed, Inc.: Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach | Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains
53% of people surveyed rank sleep as the most important behavior for a long... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| HENRY SCHEIN | 65,50 | -1,50 % | Henry Schein Q4 Earnings Rise | MELVILLE (dpa-AFX) - Henry Schein, Inc. (HSIC), a healthcare products and solutions company, Tuesday reported higher earnings and revenue for the fourth quarter compared to the same period last... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| ZIMMER BIOMET | 78,34 | +0,62 % | Zimmer Biomet Holdings, Inc.: Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer | Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7,... ► Artikel lesen | |
| PETMED EXPRESS | 1,895 | -2,42 % | PetMed Express, Inc.: PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels | DELRAY BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a strategic partnership with... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering | BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology... ► Artikel lesen | |
| TANDEM DIABETES | 17,600 | +1,15 % | FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps | ||
| QUIDELORTHO | 9,854 | -0,32 % | QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics | - Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics -- Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 166,80 | -0,39 % | Quest Diagnostics Raises 2026 EPS, Revenue Guidance | WASHINGTON (dpa-AFX) - Quest Diagnostics (DGX) said, for full year 2026, the company now expects adjusted diluted EPS in a range of $10.63 $10.83, revised from prior guidance range of $10.50... ► Artikel lesen | |
| VERU | 2,350 | +2,62 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen |
SIENTRA INC gehört der Branche Gesundheitswesen an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIENTRA INC finden Sie auf Wallstreet Online.